Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 585


A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density.

Brentnall AR, van Veen EM, Harkness EF, Rafiq S, Byers H, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J, Evans DGR.

Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32541. [Epub ahead of print]


Predicting late recurrence in ER-positive breast cancer.

Cuzick J.

Nat Rev Clin Oncol. 2019 Jul;16(7):406-408. doi: 10.1038/s41571-019-0228-y. No abstract available.


Screening performance of abbreviated versions of the UPSIT smell test.

Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE, Noyce AJ.

J Neurol. 2019 Aug;266(8):1897-1906. doi: 10.1007/s00415-019-09340-x. Epub 2019 May 3.


Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.


The percentage of high grade disease in prostate biopsies significantly improves on grade groups in prediction of prostate cancer death.

Berney DM, Beltran L, Sandu H, Soosay G, Møller H, Scardino P, Murphy J, Ahmed A, Cuzick J; Transatlantic Prostate Group.

Histopathology. 2019 Apr 29. doi: 10.1111/his.13888. [Epub ahead of print]


Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R.

Bone. 2019 Jul;124:83-88. doi: 10.1016/j.bone.2019.04.016. Epub 2019 Apr 24.


Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.

Kammerer-Jacquet SF, Ahmad A, Møller H, Sandu H, Scardino P, Soosay G, Beltran L, Cuzick J, Berney DM.

Mod Pathol. 2019 Apr 11. doi: 10.1038/s41379-019-0268-y. [Epub ahead of print]


Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.

Evans DGR, Harkness EF, Brentnall AR, van Veen EM, Astley SM, Byers H, Sampson S, Southworth J, Stavrinos P, Howell SJ, Maxwell AJ, Howell A, Newman WG, Cuzick J.

Breast Cancer Res Treat. 2019 Jul;176(1):141-148. doi: 10.1007/s10549-019-05210-2. Epub 2019 Apr 2.


A response to "Personalised medicine and population health: breast and ovarian cancer".

Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E.

Hum Genet. 2019 Mar;138(3):287-289. doi: 10.1007/s00439-019-01984-z. Epub 2019 Feb 27. No abstract available.


Prediction of reader estimates of mammographic density using convolutional neural networks.

Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG, Astley SM.

J Med Imaging (Bellingham). 2019 Jul;6(3):031405. doi: 10.1117/1.JMI.6.3.031405. Epub 2019 Jan 31.


Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8.


The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing.

Lo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E, Hopper JL, Trainer AH, Mann GB, Bickerstaffe A, Antoniou AC, Cuzick J, Phillips KA.

JMIR Form Res. 2018 Nov 7;2(2):e24. doi: 10.2196/formative.9935.


De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy537. [Epub ahead of print] No abstract available.


Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry.

Beltran L, Ahmad AS, Sandu H, Kudahetti S, Soosay G, Møller H, Cuzick J, Berney DM; Transatlantic Prostate Group.

Am J Surg Pathol. 2019 Mar;43(3):361-368. doi: 10.1097/PAS.0000000000001202.


Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply.

Brentnall AR, Buist DSM, Cuzick J.

JAMA Oncol. 2019 Jan 1;5(1):111. doi: 10.1001/jamaoncol.2018.5102. No abstract available.


Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention.

Pegington M, Evans DG, Howell A, Donnelly LS, Wiseman J, Cuzick JM, Harvie MN.

Eur J Cancer Prev. 2018 Nov 15. doi: 10.1097/CEJ.0000000000000493. [Epub ahead of print]


Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2019 May 15;144(10):2587-2595. doi: 10.1002/ijc.31976. Epub 2018 Dec 24.


Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Brenner A, Arribas M, Cuzick J, Jairath V, Stanworth S, Ker K, Shakur-Still H, Roberts I.

Trials. 2018 Oct 1;19(1):533. doi: 10.1186/s13063-018-2900-4.


Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.


Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.

Elife. 2018 Sep 4;7. pii: e37294. doi: 10.7554/eLife.37294.

Supplemental Content

Loading ...
Support Center